Rabeprazole Applications
Online Submissions: http://www.wjgnet.com/1948-9358office wjd@wjgnet.com doi:10.4239/wjd.v2.i12.217
World J Diabetes 2011 December 15; 2(12): 217-220 ISSN 1948-9358 (online) © 2011 Baishideng. All rights reserved.
BRIEF ARTICLE
Are proton pump inhibitors a new antidiabetic drug? A cross sectional study
Diana Boj-Carceller, Pilar Bocos-Terraz, Miguel Moreno-Vernis, Alejandro Sanz-Paris, Pablo Trincado-Aznar, Ramón Albero-Gamboa
Diana Boj-Carceller, Alejandro Sanz-Paris, Pablo TrincadoAznar, Ramón Albero-Gamboa, Endocrinology and Nutrition Unit, Hospital Miguel Servet, 50009 Zaragoza, Spain Pilar Bocos-Terraz, Hormonal Unit, Hospital Miguel Servet, 50009 Zaragoza, Spain Miguel Moreno-Vernis, Clinical Documentation and Archives Unit, Hospital Miguel Servet, 50009 Zaragoza, Spain Author contributions: Boj-Carceller D and Bocos-Terraz P conceived and designed the study, performed the analysis and interpretation of data and wrote the manuscript; Moreno-Vernis M collected the data and gave administrative support; Sanz-Paris A, Trincado-Aznar P and Albero-Gamboa R gave a critical revision of the article; all authors approved the version of the manuscript to be published. Correspondence to: Diana Boj-Carceller, Dr�, Endocrinology and Nutrition Unit, Hospital Miguel Servet, Paseo Isabel la Católica, 1-3, 50009 Zaragoza, Spain. dianna_bc@hotmail.com Telephone: +34-976-765500-2164 Fax: +34-976-765509 Received: July 4, 2011 Revised: October 2, 2011 Accepted: October 10, 2011 Published online: December 15, 2011
-0.��. People who used PPIs with some type of insu0.��. lin therapy had a HbA1c reduction by -0.�%, 95% CI: -0.12 to -1.��. �or the rest of subgroup analysis based 1.��. on the antidiabetic drug used, PPI consumption always exhibited lower HbA1c levels. CONCLUSION: PP�s seems to be consistentl� associated with better glycemic control in type 2 diabetes. �bA�c reduction observed is similar to incretin-based therapies�
© 2011 Baishideng. All rights reserved.
World J Diabetes 2011 December 15; 2(12): 217-220 ISSN 1948-9358 (online) © 2011 Baishideng. All rights reserved.
BRIEF ARTICLE
Are proton pump inhibitors a new antidiabetic drug? A cross sectional study
Diana Boj-Carceller, Pilar Bocos-Terraz, Miguel Moreno-Vernis, Alejandro Sanz-Paris, Pablo Trincado-Aznar, Ramón Albero-Gamboa
Diana Boj-Carceller, Alejandro Sanz-Paris, Pablo TrincadoAznar, Ramón Albero-Gamboa, Endocrinology and Nutrition Unit, Hospital Miguel Servet, 50009 Zaragoza, Spain Pilar Bocos-Terraz, Hormonal Unit, Hospital Miguel Servet, 50009 Zaragoza, Spain Miguel Moreno-Vernis, Clinical Documentation and Archives Unit, Hospital Miguel Servet, 50009 Zaragoza, Spain Author contributions: Boj-Carceller D and Bocos-Terraz P conceived and designed the study, performed the analysis and interpretation of data and wrote the manuscript; Moreno-Vernis M collected the data and gave administrative support; Sanz-Paris A, Trincado-Aznar P and Albero-Gamboa R gave a critical revision of the article; all authors approved the version of the manuscript to be published. Correspondence to: Diana Boj-Carceller, Dr�, Endocrinology and Nutrition Unit, Hospital Miguel Servet, Paseo Isabel la Católica, 1-3, 50009 Zaragoza, Spain. dianna_bc@hotmail.com Telephone: +34-976-765500-2164 Fax: +34-976-765509 Received: July 4, 2011 Revised: October 2, 2011 Accepted: October 10, 2011 Published online: December 15, 2011
-0.��. People who used PPIs with some type of insu0.��. lin therapy had a HbA1c reduction by -0.�%, 95% CI: -0.12 to -1.��. �or the rest of subgroup analysis based 1.��. on the antidiabetic drug used, PPI consumption always exhibited lower HbA1c levels. CONCLUSION: PP�s seems to be consistentl� associated with better glycemic control in type 2 diabetes. �bA�c reduction observed is similar to incretin-based therapies�
© 2011 Baishideng. All rights reserved.
References: December 15, 2011|Volume 2|Issue 12| Boj-Carceller D et al � Antidiabetic properties o� proton pump inhibitors December 15, 2011|Volume 2|Issue 12|